Auto-generated from public data. Not the firm's stated position.
Karolinska appears to focus on early-stage biotech and healthtech companies in Sweden, with particular emphasis on therapeutic development across CNS, oncology, and medical devices. Recent portfolio activity suggests concentration in pre-seed and seed rounds with check sizes ranging from €0.1M to €1.5M.
Generated 14 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Oct 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.